[Molecular Targeted Therapies for Hereditary Cancer Syndrome]

Area of Science:

• Oncology
• Genetics
• Pharmacology

Background:

• Molecular targeted drugs have significantly advanced cancer therapy.
• New drugs are emerging that target genes responsible for hereditary cancer syndromes.
• These targeted therapies offer personalized treatment strategies for hereditary and sporadic cancers with similar biological profiles.

Purpose of the Study:

• To review molecular targeted drugs with potential efficacy in hereditary cancer syndromes.
• To highlight the role of genetic testing as a biomarker for predicting drug response.

Main Methods:

• Literature review of molecular targeted drugs.
• Focus on drugs associated with hereditary cancer syndrome genes.
• Inclusion of immune checkpoint inhibitors and other targeted agents.

Main Results:

• Anti-PD-1 antibodies show potential for Lynch syndrome.
• PARP inhibitors are effective for hereditary breast and ovarian cancer syndromes.
• Multi-kinase inhibitors are relevant for multiple endocrine neoplasia type 2.

Conclusions:

• Genetic testing for hereditary cancer syndromes serves as a biomarker for predicting molecular targeted drug efficacy.
• Targeted therapies, including immune checkpoint inhibitors and PARP inhibitors, represent a significant advancement in managing hereditary cancers.